Top-Rated StocksTop-RatedMost-Upgraded StocksMost-UpgradedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis $74.54 +0.04 (+0.05%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$72.90▼$75.2850-Day Range$22.00▼$77.9852-Week Range$20.33▼$78.87Volume1.42 million shsAverage Volume2.55 million shsMarket Capitalization$11.08 billionP/E RatioN/ADividend YieldN/APrice Target$74.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Insmed alerts: Email Address Insmed MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside0.1% Downside$74.50 Price TargetShort InterestBearish10.01% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.80Based on 7 Articles This WeekInsider TradingSelling Shares$13.76 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.71) to ($3.79) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.16 out of 5 starsMedical Sector373rd out of 936 stocksPharmaceutical Preparations Industry175th out of 436 stocks 2.5 Analyst's Opinion Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 16 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInsmed has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.01% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Insmed has recently increased by 15.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInsmed has received a 68.20% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Aminoglycosides", "Preclinical research services for physical health", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Insmed is -1.28. Previous Next 3.2 News and Social Media Coverage News SentimentInsmed has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Insmed this week, compared to 5 articles on an average week.Search InterestOnly 9 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows20 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is an increase of 43% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,762,062.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Insmed is held by insiders.Read more about Insmed's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($4.71) to ($3.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -14.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -14.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Insmed's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Insmed Stock (NASDAQ:INSM)Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More INSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INSM Stock News HeadlinesJuly 18, 2024 | marketbeat.comStock Rotation is Underway: Here are the Winners Moving Forward (INSM)The CPI report sparked a massive sector rotation; investors are shedding overbought big tech names like Microsoft and NVIDIA in favor of risk-on assets.July 26 at 10:07 AM | msn.comThese Signs Show Which Stocks Are Having A Hidden Rally, Says Mark MinerviniJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 21, 2024 | markets.businessinsider.comExploring Insmed's Key Growth Drivers...July 19, 2024 | finance.yahoo.comInsmed Incorporated (INSM)July 19, 2024 | benzinga.comHere's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth TodayJuly 19, 2024 | americanbankingnews.comBrokerages Set Insmed Incorporated (NASDAQ:INSM) Price Target at $74.50July 17, 2024 | americanbankingnews.comInsmed (NASDAQ:INSM) Reaches New 1-Year High on Analyst UpgradeJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 5, 2024 | prnewswire.comInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 3, 2024 | prnewswire.comAdditional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis ConferenceJune 27, 2024 | prnewswire.comInsmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025June 7, 2024 | prnewswire.comInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5, 2024 | prnewswire.comInsmed To Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 30, 2024 | prnewswire.comInsmed to Host Commercial Webinar on June 4, 2024May 30, 2024 | prnewswire.comInsmed Announces Pricing of $650 Million Public Offering of Common StockMay 29, 2024 | marketwatch.comInsmed Shares Extend Gains, Reach 23-Year HighMay 29, 2024 | finance.yahoo.comInsmed PT Raised to $67 at TD CowenSee More Headlines Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INSM CUSIPN/A CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Target$74.50 High Stock Price Target$102.00 Low Stock Price Target$42.00 Potential Upside/Downside+1.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($5.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-749,570,000.00 Net Margins-236.74% Pretax Margin-235.89% Return on EquityN/A Return on Assets-56.78% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.61 Sales & Book Value Annual Sales$305.21 million Price / Sales35.88 Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-31.76Miscellaneous Outstanding Shares148,600,000Free Float141,769,000Market Cap$10.95 billion OptionableOptionable Beta1.16 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. William H. Lewis J.D. (Age 50)Pres, CEO & Chairman Mr. Paolo Tombesi (Age 55)Chief Financial Officer Ms. Christine A. Pellizzari J.D. (Age 51)Chief Legal Officer & Corp. Sec. Mr. Roger Adsett (Age 50)Chief Commercial Officer Dr. Paul D. Streck (Age 55)Advisor Key CompetitorsArena PharmaceuticalsNASDAQ:ARNAForty SevenNASDAQ:FTSVChemoCentryxNASDAQ:CCXITG TherapeuticsNASDAQ:TGTXPTC TherapeuticsNASDAQ:PTCTView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 323,772 shares on 7/26/2024Ownership: 0.221%EFG Asset Management North America Corp.Sold 18,640 shares on 7/26/2024Ownership: 0.036%Legato Capital Management LLCSold 5,191 shares on 7/26/2024Ownership: 0.030%Atomi Financial Group Inc.Sold 6,330 shares on 7/26/2024Ownership: 0.015%&PARTNERSBought 4,477 shares on 7/24/2024Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions INSM Stock Analysis - Frequently Asked Questions How have INSM shares performed this year? Insmed's stock was trading at $30.99 at the start of the year. Since then, INSM stock has increased by 140.5% and is now trading at $74.54. View the best growth stocks for 2024 here. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.16. Insmed's revenue was up 15.8% compared to the same quarter last year. What is Will Lewis' approval rating as Insmed's CEO? 14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees. Who are Insmed's major shareholders? Top institutional shareholders of Insmed include Assenagon Asset Management S.A. (0.26%), Allspring Global Investments Holdings LLC (0.22%), Hennion & Walsh Asset Management Inc. (0.08%) and Raymond James & Associates (0.04%). Insiders that own company stock include William Lewis, Melvin Md Sharoky, Roger Adsett, John Drayton Wise, Sara Bonstein, Martina MD Flammer, Michael Alexander Smith, Orlov S Nicole Schaeffer and David R Brennan. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD) and OPKO Health (OPK). This page (NASDAQ:INSM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
